newsThe Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4…
27 June 2016 | By Victoria White (European Pharmaceutical Review)
The Anacor acquisition adds crisaborole, a differentiated non-steroidal topical PDE4 inhibitor with anti-inflammatory properties, to Pfizer's pipeline...